A Paradigm-Shifting Platform Technology I believe that that many are focusing on the negative and are letting fear and doubt cause unnecessary stress at a time when we should all be exited about the future . ( and there is also Digi, who for those who don’t know and are new here, he is a trader that will change from exuberance to complete damnation in order to facilitate his current trade) There was a huge wealth of knowledge to be discovered in the MD&A.
We should also focus on the valuation that the market has just assigned to Denali, a company that is in a similar line of business with a vector that is arguably not as proficient as ours and runs into toxicity issues to accomplish the same level of BBB penetration as Xb3. We simply have to wait for the market to realize the superiority of our vector and the stock price will jump significantly as a result. It sure seems that the team has prioritized our internal programs, partnerships and collaborations to this end and to show to the world that we do indeed have a Paradigm-Shifting Platform Technology.
“As a patient-oriented, science-driven company, we are adopting a highly proactive business plan with the primary focus being the advancement of carefully selected, in-house discovery development programs for the treatment of specific CNS-related diseases. We believe that our programs have the potential to bring forward new medicines, impacting patients and returning value for shareholders. Key to our philosophy is a dedication to science as the driver of what we do, with our mission being to develop new medicines for patients suffering from CNS-related diseases and disorders.”
The Team has a very specific “Strategy” in mind and are using that strategy to advance the science and thus ultimately the stock price.
“Our goal is to become the leading Blood-Brain Barrier company by enabling the treatment of patients with previously untreatable brain diseases, what we believe to be the last frontier in CNS medicine. To achieve this goal, we are pursuing the following strategic actions
• Advance the Development of Our xB3-001 Program
• Advance the Preclinical Proof of Concept in Animal Models With Our xB3-002 program
• Advance Our xB3-007 Program Targeting Neurodegenerative Diseases.
• Continue to Identify Other Cutting-Edge BBB Targets.
• Capitalize on Our New Location and Pursue Opportunities to Further Expand Our Presence and Operations in the United States.”
I believe that there will be many news releases that will occur that will show that we are indeed the premier company to provide a vector for CNS medicine. Those news release will happen at strategic times following successes of both internal programs and strategic partnerships. But make no mistake, they will happen at a time of most strategic impact to the business model.